This site is intended for health professionals only

Blood-thinning drug may be approved


A drug made from genetically-engineered goats’ milk may be approved as a blood thinner by the US Food and Drug Administration (FDA).

The anti-clotting drug Atryn is intended to treat hereditary antithrombin deficiency, and is made by GTC Biotherapeutics from human proteins inserted into goats’ milk.

A second clot-disorder treatment, CSL’s Riastap, also appears safe and effective the FDA says, although both will need further after-market study.

The FDA is to consider a recommendation from a panel of outside advisers that both drugs are safe and effective. The agency usually accepts the the panel’s advice.

Atrynis is part of a series of anti-clotting drugs that GTC is developing and is the company’s first to be submitted for approval in the US.

Hereditary antithrombin deficiency is a condition in which excessive clotting can be caused by irregular protein levels. The treatment is made using a human protein produced in milk from genetically-engineered goats.

Traditional blood thinners such as warfarin are unsuitable for patients undergoing high-risk surgeries or giving birth. The FDA says that on balance, Atryn has an “acceptable” level of risk.

Copyright Press Association 2009


Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine